Integrated Whole Genome and Transcriptome Sequencing as a Framework for Pediatric and Adolescent AML Diagnosis and...

Area of Science:

• Genomics
• Molecular Diagnostics
• Pediatric Oncology

Background:

• Pediatric acute myeloid leukemia (AML) has unique genetic features influencing prognosis and treatment.
• Rare genetic abnormalities in pediatric AML necessitate advanced molecular diagnostic tools.
• Current diagnostic methods may not capture the full spectrum of genetic alterations.

Purpose of the Study:

• To develop and evaluate an integrated whole genome sequencing (WGS) and whole transcriptome sequencing (WTS) clinical workflow for pediatric AML.
• To compare the diagnostic utility of the integrated WGS and WTS (iWGS-WTS) approach against conventional methods.
• To assess the potential of iWGS-WTS for precise disease classification and risk stratification in pediatric AML.

Main Methods:

• Implementation of a routine clinical workflow integrating WGS and WTS for pediatric AML samples.
• Systematic evaluation of the iWGS-WTS approach against cytogenetics and standard molecular diagnostics.
• Analysis of WGS for structural variants, mutations, and copy number alterations.
• Analysis of WTS for gene expression patterns, allele-specific expression, and signatures.

Main Results:

• The iWGS-WTS approach significantly improved the identification of clinically relevant genetic alterations in pediatric AML.
• This integrated method provided enhanced precision in disease classification and risk assessment compared to conventional diagnostics.
• Optimization of workflow and bioinformatics pipelines demonstrated potential for reduced testing turnaround time.

Conclusions:

• The integrated WGS and WTS (iWGS-WTS) workflow is a practical and superior alternative for pediatric AML diagnosis.
• This approach enhances the accuracy of molecular profiling, aiding clinical decision-making.
• iWGS-WTS facilitates more precise management of pediatric AML by providing comprehensive genetic insights.